Regulatory & Legal

Pfizer projects lower 2026 earnings as COVID sales wane and patents expire, shifting focus to a multi-billion dollar R&D push for future growth.

Falco Resources restructures key debt and names a new board chair, gaining critical runway to advance its massive Horne 5 gold project in Quebec.

A new partnership between Beacon Biosignals and Harmony Biosciences will use AI to objectively measure sleepiness, offering new hope for hypersomnia patients.

After bombshell allegations and a stock plunge, Rezolve AI faces a major lawsuit investigation, raising critical questions about AI hype and corporate honesty.

Biotech Immunome plans a massive stock offering. A deep dive into the high-stakes bet on its cancer pipeline and what it means for investors.

Kodiak Sciences is raising crucial capital with a stock offering, diluting investors but fueling its late-stage retinal drugs. Is this a necessary lifeline or a red flag?

Tiziana's CEO doubles down with a major share purchase, signaling deep faith in a novel MS drug, even as market signals send mixed messages.

A new report forecasts modest 2.6% growth for US construction in 2026, driven by data centers, water, and aviation, but challenged by major hurdles.

As the year-long TRANSFORMERS crossover ends, we analyze the strategy, tech, and financial impact of a new benchmark in mobile gaming partnerships.

Bringer Air Cargo's new direct route to Navegantes isn't just a flight path; it's a strategic move reshaping supply chains for Brazil's economic engine.

A family transformed personal loss into a record-breaking charity. We decode the growth signals behind a grassroots toy drive that’s scaling across Canada.

Sweeping reforms pulled Florida's property insurance market from the brink of collapse. We decode the fixes, the capital influx, and the risks that still loom.

An Indiana biotech prepares for biotech's biggest stage, showcasing a pipeline that offers new hope for chronic endocrine and metabolic disorders.

AMTD Digital's subsidiary is on a global hotel buying binge, but a history of extreme stock volatility and underlying financial risks raise serious questions.

After a NYSE delisting, FOXO Technologies is betting big on healthcare acquisitions. Is this a savvy turnaround or a high-risk gamble for investors?

Quince Therapeutics' Phase 3 trial completion for Ataxia-Telangiectasia offers hope, but the real story is its innovative red blood cell drug delivery platform.

How a strategic pharma pact between Duchesnay and Mochida to bring a vital pregnancy drug to Japan offers a blueprint for stable returns in complex markets.

Natera's legal retreat solidifies a major victory for NeoGenomics, clearing the runway for its RaDaR ST launch and shaking the diagnostic patent landscape.

A public fund's major investment in Consensys, the firm behind MetaMask, signals growing institutional confidence in Web3's foundational infrastructure.

A landmark green ammonia project in Spain offers a blueprint for industrial decarbonization, holding key strategic lessons for the biopharmaceutical sector.